Scientists in Germany have made significant progress in developing a nasal vaccine that can effectively shut down Covid-19 infections by targeting the virus's entry point into the body. The vaccine, which uses a live but weakened form of the coronavirus, has shown promising results in hamster studies, achieving "sterilizing immunity" and preventing illness.
The vaccine works by boosting mucosal immunity, specifically in the upper airways where the virus enters the body. Researchers believe that this approach can provide a long-lasting defense against Covid-19, which is currently only achieved through blood-based vaccines.
In experiments conducted on hamsters, two doses of the nasal vaccine were found to block the virus from copying itself in the animals' upper airways, demonstrating sterilizing immunity and preventing illness. The researchers also discovered that this vaccine can create immune antibodies that are better equipped to deal with new variants of Covid-19.
While the results are encouraging, experts caution that more testing is needed before the vaccine can be approved for human use. The study began in 2021, prior to the emergence of the Omicron variant, and while the live weakened vaccine still performed well against the newer strain, its effectiveness was diminished.
The German team behind the vaccine is now working on phase I clinical trials with a partner company called RocketVax, but other nasal vaccines are already in various stages of testing. Several candidates are nearing completion or have recently completed human studies, including a recombinant vaccine that can be produced cheaply in chicken eggs and another using a live but weakened version of the virus.
Experts welcome these developments, as the current pandemic highlights the need for improved respiratory infection treatments. While there is still much work to be done, the progress made by this innovative approach offers hope for future generations of Covid-19 vaccines that can effectively prevent illness and transmission.
However, researchers are also aware of the challenges associated with inhaled vaccines, such as respiratory infections proving difficult targets. The German team acknowledges the need for caution, emphasizing that even a strongly attenuated virus is still a real one that requires careful handling.
As researchers continue to develop and test these innovative nasal vaccines, they hold out hope that they can provide a more effective solution against Covid-19, especially in vulnerable populations. With ongoing progress and further testing on the horizon, it's possible that a new generation of respiratory infection treatments will soon be available to combat this global health threat.
The vaccine works by boosting mucosal immunity, specifically in the upper airways where the virus enters the body. Researchers believe that this approach can provide a long-lasting defense against Covid-19, which is currently only achieved through blood-based vaccines.
In experiments conducted on hamsters, two doses of the nasal vaccine were found to block the virus from copying itself in the animals' upper airways, demonstrating sterilizing immunity and preventing illness. The researchers also discovered that this vaccine can create immune antibodies that are better equipped to deal with new variants of Covid-19.
While the results are encouraging, experts caution that more testing is needed before the vaccine can be approved for human use. The study began in 2021, prior to the emergence of the Omicron variant, and while the live weakened vaccine still performed well against the newer strain, its effectiveness was diminished.
The German team behind the vaccine is now working on phase I clinical trials with a partner company called RocketVax, but other nasal vaccines are already in various stages of testing. Several candidates are nearing completion or have recently completed human studies, including a recombinant vaccine that can be produced cheaply in chicken eggs and another using a live but weakened version of the virus.
Experts welcome these developments, as the current pandemic highlights the need for improved respiratory infection treatments. While there is still much work to be done, the progress made by this innovative approach offers hope for future generations of Covid-19 vaccines that can effectively prevent illness and transmission.
However, researchers are also aware of the challenges associated with inhaled vaccines, such as respiratory infections proving difficult targets. The German team acknowledges the need for caution, emphasizing that even a strongly attenuated virus is still a real one that requires careful handling.
As researchers continue to develop and test these innovative nasal vaccines, they hold out hope that they can provide a more effective solution against Covid-19, especially in vulnerable populations. With ongoing progress and further testing on the horizon, it's possible that a new generation of respiratory infection treatments will soon be available to combat this global health threat.